Teva

Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) saw its share price rise by 12.8% yesterday, amid high trading volume, to its highest level in five years. The stock price of $15.74…

With the recovery of the generic drug market in the United States Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) It ended the first quarter of 2024 with revenues of $3.81 billion, an…

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET.…

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Richard Francis believes that the Israeli drug-maker is entering an era of growth, is bullish about its ability to achieve good value for the sale of its…

For the first time since 2016, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) enlarged its workforce during 2023. The Israeli company had 36,472 employees at the end of 2023, up 1,347 or 3.8% from 2022,…

More and more analysts are expressing confidence in the stock of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA). Data from "The Wall street Journal" shows that just three months ago the analysts' consensus…

At the end of 2023, Israeli insurance and finance group The Phoenix Holdings' stake in Teva was 5.4%. Insurance and finance group The Phoenix Holdings (TASE: PHOE)…

After just over a year in the job, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Richard Francis can afford a smile. For the first time in three and a half years the Israeli pharmaceuticals company is…

Israel's most profitable company on Wall Street in 2023 is somewhat surprising. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) recorded a non-GAAP net profit of $1.76 billion in the first nine month of 2023…

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Israeli company Biolojic Design have signed a collaboration agreement. Teva will complete development of Biolojic's antibody-based therapy for the treatment…